No. | Treatment intervals (days)2 | Possible adverse reaction | Possible patient benefit | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
leukocytes | platelets | AST | ALT | T-BIL | ALBI stage | Tumor response3 | Recurrence type | PFS (months) | OS (months) | ||
1 | –12 | ↓ | N | ↑ | N | ↑ | N | CR | IDR | 44.8 | 71.9 |
2 | 20 | ↓ | N | N | N | N | N | CR | IDR | 15.6 | 30.0 |
3 | 26 | ↓ | N | N | N | N | N | PD | IDR | 12.0 | 60.9 |
4 | 34 | N | N | N | N | N | N | CR | IDR | 28.7 | 61.2 |
5 | 20 | ↓ | N | N | N | ↑ | N | CR | No | 58.8 | 58.8 |
6 | –4 | N | N | N | N | N | N | CR | IDR | 24.7 | 46.2 |
7 | −11 | ↓ | ↓ | N | N | N | N | CR | IDR | 20.1 | 31.3 |
8 | 19 | N | ↓ | N | N | N | First↓then↑ | CR | No | 34.1 | 34.3 |
9 | 45 | N | N | N | N | ↑ | N | CR | IDR | 17.1 | 34.3 |
10 | 48 | ↓ | N | N | N | N | ↓ | SD | LTP | 13.0 | 23.9 |
11 | 48 | ↓ | N | N | N | N | N | CR | No | 23.3 | 23.3 |
12 | 60 | N | N | N | N | N | First↓then↑ | PD | LTP | 4.2 | 15.1 |
13 | 13 | N | ↓ | N | N | N | N | CR | No | 16.9 | 16.9 |
14 | 41 | N | ↓ | ↑ | ↑ | N | First↓then↑ | PD | IDR | 2.8 | 18.5 |
15 | 55 | N | N | N | N | ↑ | N | CR | No | 22.5 | 22.5 |
Total4 | 26 (4–60) | / | / | / | / | / | 4/11 | 11/0/1/3 | 2/8/5 | 20.1 (2.8–45.1) | 31.3 (15.1–71.9) |